Takeda/Ovid Broaden Pioneering CH24H Inhibitor To Rare Epilepsies

Takeda and partner Ovid are planning new trials in rare pediatric indications for their first-in-class epilepsy drug, including in the increasingly competitive area of Dravet syndrome.